AC Immune SA (ACIU): Price and Financial Metrics


AC Immune SA (ACIU): $3.88

0.49 (+14.45%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ACIU POWR Grades


  • Sentiment is the dimension where ACIU ranks best; there it ranks ahead of 97.8% of US stocks.
  • ACIU's strongest trending metric is Growth; it's been moving up over the last 177 days.
  • ACIU's current lowest rank is in the Quality metric (where it is better than 4.56% of US stocks).

ACIU Stock Summary

  • AC Immune SA's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 6.17% of US listed stocks.
  • ACIU's price/sales ratio is 446.83; that's higher than the P/S ratio of 99.1% of US stocks.
  • As for revenue growth, note that ACIU's revenue has grown -96.06% over the past 12 months; that beats the revenue growth of merely 1% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to AC Immune SA are AGTC, VBLT, SYBX, AYLA, and ALT.
  • ACIU's SEC filings can be seen here. And to visit AC Immune SA's official web site, go to www.acimmune.com.

ACIU Price Target

For more insight on analysts targets of ACIU, see our ACIU price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.23 Average Broker Recommendation 1.17 (Strong Buy)

ACIU Stock Price Chart Interactive Chart >

Price chart for ACIU

ACIU Price/Volume Stats

Current price $3.88 52-week high $12.61
Prev. close $3.39 52-week low $2.06
Day low $3.29 Volume 431,300
Day high $3.90 Avg. volume 110,566
50-day MA $3.28 Dividend yield N/A
200-day MA $4.71 Market Cap 324.18M

AC Immune SA (ACIU) Company Bio


AC Immune SA, a clinical stage Swiss-based biopharmaceutical company, focuses on neurodegenerative diseases with three product candidates in clinical trials. It designs, discovers, and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by mis-folding proteins. The company was founded in 2003 and is based in Lausanne, Switzerland.


ACIU Latest News Stream


Event/Time News Detail
Loading, please wait...

ACIU Latest Social Stream


Loading social stream, please wait...

View Full ACIU Social Stream

Latest ACIU News From Around the Web

Below are the latest news stories about AC Immune SA that investors may wish to consider to help them evaluate ACIU as an investment opportunity.

Could The AC Immune SA (NASDAQ:ACIU) Ownership Structure Tell Us Something Useful?

If you want to know who really controls AC Immune SA ( NASDAQ:ACIU ), then you'll have to look at the makeup of its...

Yahoo | February 21, 2022

H.C. Wainwright Thinks AC Immune SA’s Stock is Going to Recover

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on AC Immune SA (ACIU – Research Report), with a price target of $16.00. The company's shares closed last Tuesday at $4.48, close to its 52-week low of $4.04. According to TipRanks.com, Fein has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -4.3% and a 33.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Amylyx Pharmaceuticals, Inc., and Deciphera Pharmaceuticals. AC Immune SA has an analyst consensus of Moderate Buy, with a price target consensus of $15.00.

Brian Anderson on TipRanks | February 15, 2022

J&J/AC Immune potential Alzheimer’s vaccine''s high dose shows promise in phase 1b/2a trial

AC Immune (ACIU) reported interim 10-week data from a high-dose cohort of a phase 1b/2a trial evaluating ACI-35.030, a phosphorylated-Tau (pTau) vaccine candidate in people with…

Seeking Alpha | February 15, 2022

AC Immune-Janssen Partnered Alzheimer''s Vaccine Shows Tau-Specific Antibodies In Early-Stage Trial

AC Immune SA (NASDAQ: ACIU ) and partner Janssen, a unit of Johnson & Johnson (NYSE: JNJ ), have found that an early-stage Alzheimer''s vaccine spurs induction of antibodies that attack a type of tau, a protein in the brain that contributes to the disease. The interim data for ACI-35.030 come from the high-dose group … Full story available on Benzinga.com

Benzinga | February 15, 2022

AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer''s Vaccine in High-dose Cohort

Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment ACI-35.030 continues to be well tolerated with no clinically relevant safety concerns observed in low-, mid- or high-dose cohorts to date Interim data support plans for further late-stage development LAUSANNE, Switzerland, Feb. 15, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU ), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced new interim 10-week data from the high-dose cohort of a placebo-controlled Phase 1b/2a trial evaluating ACI-35.030, a first-in-class phosphorylated-Tau (pTau) vaccine candidate in participants with early Alzheimer''s disease (AD). The Company previously reported interim d...

Benzinga | February 15, 2022

Read More 'ACIU' Stories Here

ACIU Price Returns

1-mo N/A
3-mo -3.00%
6-mo -21.62%
1-year -52.63%
3-year -30.09%
5-year -55.91%
YTD -21.62%
2021 -4.26%
2020 -39.32%
2019 -9.84%
2018 -26.17%
2017 -1.39%

Continue Researching ACIU

Want to see what other sources are saying about AC Immune SA's financials and stock price? Try the links below:

AC Immune SA (ACIU) Stock Price | Nasdaq
AC Immune SA (ACIU) Stock Quote, History and News - Yahoo Finance
AC Immune SA (ACIU) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4519 seconds.